- Home
- MDGL vs EXEL Comparison
MDGL vs EXEL Comparison
Compare MDGL & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | EXEL |
|---|---|---|
| Founded | 2011 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 11.7B |
| IPO Year | 2005 | 2000 |
Fundamental Metrics
Financial Performance| Metric | MDGL | EXEL |
|---|---|---|
| Price | $435.90 | $40.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 21 |
| Target Price | ★ $674.45 | $46.45 |
| AVG Volume (30 Days) | 327.9K | ★ 2.8M |
| Earning Date | 05-19-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.32 | ★ 57.95 |
| EPS | N/A | ★ 2.78 |
| Revenue | $180,133,000.00 | ★ $452,477,000.00 |
| Revenue This Year | $58.70 | $13.66 |
| Revenue Next Year | $46.88 | $13.73 |
| P/E Ratio | ★ N/A | $14.80 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $265.00 | $32.38 |
| 52 Week High | $615.00 | $48.74 |
Technical Indicators
Market Signals| Indicator | MDGL | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 39.04 |
| Support Level | $416.43 | $40.01 |
| Resistance Level | $446.51 | $40.92 |
| Average True Range (ATR) | 15.97 | 1.33 |
| MACD | 2.59 | -0.21 |
| Stochastic Oscillator | 56.64 | 14.12 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.